NO332847B1 - Anvendelse av NK-1 reseptor antagonister for fremstilling av et medikament for intravenos formulering for behandling og/eller forebygging av hjerne, ryggmarg eller nerveskade - Google Patents

Anvendelse av NK-1 reseptor antagonister for fremstilling av et medikament for intravenos formulering for behandling og/eller forebygging av hjerne, ryggmarg eller nerveskade Download PDF

Info

Publication number: NO332847B1
Authority: NO; Norway
Prior art keywords: brain; methyl; receptor antagonist; treatment; prevention
Prior art date: 2001-07-10

Application number

NO20040057A

Other languages

English (en)

Norwegian (no)

Other versions

NO20040057L (no

Inventor

Torsten Hoffmann

Alan John Nimmo

Pierre Vankan

Robert Vink

Andrew Sleight

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-10

Filing date

2004-01-07

Publication date

2013-01-21

2004-01-07 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-01-07 Publication of NO20040057L publication Critical patent/NO20040057L/no

2013-01-21 Publication of NO332847B1 publication Critical patent/NO332847B1/no

Links

108010040718 Neurokinin-1 Receptors Proteins 0.000 title claims abstract description 53
102000002002 Neurokinin-1 Receptors Human genes 0.000 title claims abstract description 53
239000002464 receptor antagonist Substances 0.000 title claims abstract description 50
229940044551 receptor antagonist Drugs 0.000 title claims abstract description 50
210000004556 brain Anatomy 0.000 title claims abstract description 19
238000011282 treatment Methods 0.000 title claims abstract description 18
208000028389 Nerve injury Diseases 0.000 title claims abstract description 14
230000008764 nerve damage Effects 0.000 title claims abstract description 14
230000002265 prevention Effects 0.000 title claims abstract description 11
239000003814 drug Substances 0.000 title claims description 9
229940079593 drug Drugs 0.000 title claims description 7
239000000203 mixture Substances 0.000 title claims description 7
238000009472 formulation Methods 0.000 title claims description 4
238000001990 intravenous administration Methods 0.000 title claims description 4
238000002360 preparation method Methods 0.000 title description 4
210000000278 spinal cord Anatomy 0.000 title description 2
150000003839 salts Chemical class 0.000 claims abstract description 9
239000002253 acid Substances 0.000 claims abstract description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
239000011777 magnesium Substances 0.000 claims description 8
229910052749 magnesium Inorganic materials 0.000 claims description 8
230000000144 pharmacologic effect Effects 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
HZBSJCLPYPJTHM-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-methyl-4-(2-methylphenyl)-6-piperazin-1-ylpyridine-3-carboxamide Chemical compound C=1N=C(N2CCNCC2)C=C(C=2C(=CC=CC=2)C)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HZBSJCLPYPJTHM-UHFFFAOYSA-N 0.000 claims description 2
HCNNJLLLMSVTFH-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridine-3-carboxamide Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HCNNJLLLMSVTFH-UHFFFAOYSA-N 0.000 abstract description 16
150000001875 compounds Chemical class 0.000 abstract description 10
239000000654 additive Substances 0.000 abstract description 6
159000000003 magnesium salts Chemical class 0.000 abstract description 6
239000008194 pharmaceutical composition Substances 0.000 abstract description 2
230000000996 additive effect Effects 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
241001465754 Metazoa Species 0.000 description 33
208000014674 injury Diseases 0.000 description 20
208000027418 Wounds and injury Diseases 0.000 description 17
230000006378 damage Effects 0.000 description 15
208000029028 brain injury Diseases 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 10
208000030886 Traumatic Brain injury Diseases 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
230000009529 traumatic brain injury Effects 0.000 description 9
102100024304 Protachykinin-1 Human genes 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
230000008499 blood brain barrier function Effects 0.000 description 7
210000001218 blood-brain barrier Anatomy 0.000 description 7
229940091250 magnesium supplement Drugs 0.000 description 7
206010030113 Oedema Diseases 0.000 description 6
230000035515 penetration Effects 0.000 description 6
239000000825 pharmaceutical preparation Substances 0.000 description 6
101800003906 Substance P Proteins 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 4
230000000324 neuroprotective effect Effects 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
102000003141 Tachykinin Human genes 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000007278 cognition impairment Effects 0.000 description 3
239000008298 dragée Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
238000000034 method Methods 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
230000035699 permeability Effects 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 3
108060008037 tachykinin Proteins 0.000 description 3
230000008733 trauma Effects 0.000 description 3
208000019901 Anxiety disease Diseases 0.000 description 2
206010015866 Extravasation Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010037423 Pulmonary oedema Diseases 0.000 description 2
208000020339 Spinal injury Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
102000007124 Tachykinin Receptors Human genes 0.000 description 2
108010072901 Tachykinin Receptors Proteins 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
230000006931 brain damage Effects 0.000 description 2
231100000874 brain damage Toxicity 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
230000003920 cognitive function Effects 0.000 description 2
239000003086 colorant Substances 0.000 description 2
230000006735 deficit Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000021824 exploration behavior Effects 0.000 description 2
230000036251 extravasation Effects 0.000 description 2
239000003925 fat Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000012458 free base Substances 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
-1 invert sugar Substances 0.000 description 2
230000000873 masking effect Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
230000003961 neuronal insult Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
208000005333 pulmonary edema Diseases 0.000 description 2
230000009467 reduction Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000002462 tachykinin receptor antagonist Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
239000001993 wax Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
206010069918 Bacterial prostatitis Diseases 0.000 description 1
206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
206010061183 Genitourinary tract neoplasm Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229940123821 Neurokinin 1 receptor antagonist Drugs 0.000 description 1
108010040722 Neurokinin-2 Receptors Proteins 0.000 description 1
108010040716 Neurokinin-3 Receptors Proteins 0.000 description 1
102000002003 Neurokinin-3 Receptors Human genes 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
206010036968 Prostatic pain Diseases 0.000 description 1
208000012545 Psychophysiologic disease Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
102100037342 Substance-K receptor Human genes 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
238000012382 advanced drug delivery Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004780 brain interstitium Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
230000036427 bronchial hyperreactivity Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
230000003931 cognitive performance Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000001037 epileptic effect Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000001755 magnesium gluconate Substances 0.000 description 1
229960003035 magnesium gluconate Drugs 0.000 description 1
235000015778 magnesium gluconate Nutrition 0.000 description 1
UHNWOJJPXCYKCG-UHFFFAOYSA-L magnesium oxalate Chemical compound [Mg+2].[O-]C(=O)C([O-])=O UHNWOJJPXCYKCG-UHFFFAOYSA-L 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
PFPSZGPAQFBVHZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-[(4-phenyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound ClC1=CC=CC(NC(=O)CSC=2N(C(C=3C=CN=CC=3)=NN=2)C=2C=CC=CC=2)=C1 PFPSZGPAQFBVHZ-UHFFFAOYSA-N 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000006259 organic additive Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
208000037974 severe injury Diseases 0.000 description 1
230000009528 severe injury Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003890 substance P antagonist Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000002466 tachykinin receptor agonist Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012549 training Methods 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
230000000982 vasogenic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20040057A 2001-07-10 2004-01-07 Anvendelse av NK-1 reseptor antagonister for fremstilling av et medikament for intravenos formulering for behandling og/eller forebygging av hjerne, ryggmarg eller nerveskade NO332847B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01116812		2001-07-10
PCT/EP2002/007323 WO2003006016A2 (fr)	2001-07-10	2002-07-03	Utilisation d'antagonistes du recepteur nk-1 pour le traitement des lesions cerebrales, medullaires ou nerveuses

Publications (2)

Publication Number	Publication Date
NO20040057L NO20040057L (no)	2004-01-07
NO332847B1 true NO332847B1 (no)	2013-01-21

Family

ID=8178001

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20040057A NO332847B1 (no)	2001-07-10	2004-01-07	Anvendelse av NK-1 reseptor antagonister for fremstilling av et medikament for intravenos formulering for behandling og/eller forebygging av hjerne, ryggmarg eller nerveskade

Country Status (24)

Country	Link
US (3)	US20030083345A1 (fr)
EP (2)	EP1621195A3 (fr)
JP (1)	JP2004536119A (fr)
KR (1)	KR100589106B1 (fr)
CN (1)	CN100346789C (fr)
AR (1)	AR037008A1 (fr)
AU (1)	AU2002328837B2 (fr)
BR (1)	BR0210893A (fr)
CA (1)	CA2451566C (fr)
GT (1)	GT200200143A (fr)
HK (1)	HK1068266A1 (fr)
HR (1)	HRP20031071A2 (fr)
HU (1)	HUP0401210A3 (fr)
IL (1)	IL159350A0 (fr)
MX (1)	MXPA04000278A (fr)
NO (1)	NO332847B1 (fr)
NZ (1)	NZ530107A (fr)
PA (1)	PA8549901A1 (fr)
PE (1)	PE20030238A1 (fr)
PL (1)	PL211246B1 (fr)
RU (1)	RU2304435C2 (fr)
UY (1)	UY27374A1 (fr)
WO (1)	WO2003006016A2 (fr)
ZA (1)	ZA200400138B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1303490T3 (da) *	2000-07-14	2008-08-25	Hoffmann La Roche	N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater
DK1643998T3 (da)	2003-07-03	2007-12-27	Hoffmann La Roche	NK1/NK3-antagonister til behandling af skizofreni
GB0410215D0 (en) *	2004-05-07	2004-06-09	Lescroart Pol	Nerve damage
MX2007000198A (es)	2004-07-06	2007-03-15	Hoffmann La Roche	Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
US20060030600A1 (en) *	2004-08-06	2006-02-09	Patrick Schnider	Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
EP1856052B1 (fr) *	2005-02-22	2009-09-02	F.Hoffmann-La Roche Ag	Antagonistes de nk1
EP2281556A1 (fr)	2005-02-25	2011-02-09	F. Hoffmann-La Roche AG	Comprimés avec une meilleure dispersibilité de substance des médicaments
DK1863767T3 (da) *	2005-03-23	2009-05-04	Hoffmann La Roche	Metabolitter til NK-I-antagonister til emesis
KR20150041174A (ko)	2005-11-08	2015-04-15	버텍스 파마슈티칼스 인코포레이티드	Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US7671221B2 (en)	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
US7754739B2 (en)	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
DE102007018151A1 (de) *	2007-04-16	2008-10-23	Günenthal GmbH	Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
AU2008251504B2 (en)	2007-05-09	2013-07-18	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
AU2008278273A1 (en) *	2007-07-19	2009-01-22	Adelaide Research & Innovation Pty Ltd	Method for reducing intracranial pressure
DK2639224T3 (en)	2007-12-07	2016-10-17	Vertex Pharma	A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
EP3170818B1 (fr)	2007-12-07	2020-02-19	Vertex Pharmaceuticals Incorporated	Formes solides d'acide benzoïque 3-(6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl)
WO2009108657A2 (fr)	2008-02-28	2009-09-03	Vertex Pharmaceuticals Incorporated	Dérivés hétéroaryles convenant comme modulateurs du cftr
GB0808747D0 (en) *	2008-05-14	2008-06-18	Glaxo Wellcome Mfg Pte Ltd	Novel compounds
HUE056525T2 (hu)	2010-04-07	2022-02-28	Vertex Pharma	3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
CA2914515C (fr)	2013-07-02	2018-12-11	Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)	Procede de prevention et/ou de traitement de l'encephalopathie traumatique chronique-i
EP3016657B1 (fr) *	2013-07-02	2019-06-26	Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro)	Procédé pour la prévention et/ou le traitement de l'encéphalopathie traumatique chronique-ii
US20160129007A1 (en) *	2013-07-02	2016-05-12	Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)	Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - IV
WO2015068744A1 (fr)	2013-11-08	2015-05-14	キッセイ薬品工業株式会社	Dérivé de carboxyméthylpipéridine
US10231932B2 (en)	2013-11-12	2019-03-19	Vertex Pharmaceuticals Incorporated	Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
TWI649307B (zh)	2014-05-07	2019-02-01	日商橘生藥品工業股份有限公司	Cyclohexylpyridine derivative
DK3221692T3 (da)	2014-11-18	2021-08-23	Vertex Pharma	Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi
CA3089662A1 (fr) *	2018-02-02	2019-08-08	Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)	Formulations parenterales et leurs utilisations
KR101970099B1 (ko) *	2018-02-07	2019-04-17	한국과학기술연구원	척수 손상의 예방 및 치료용 조성물
KR102005019B1 (ko) *	2018-04-04	2019-07-31	한국과학기술연구원	뇌졸중의 예방 및 치료용 조성물
EP4017589A4 (fr) *	2019-08-23	2023-09-20	Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro)	Méthodes thérapeutiques et utilisations associées

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4745123A (en) *	1986-02-18	1988-05-17	Warner-Lambert Company	Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
IL111002A (en) *	1993-09-22	1998-09-24	Glaxo Group Ltd	History of piperidine, their preparation and the pharmaceutical preparations containing them
US6175013B1 (en) *	1994-06-10	2001-01-16	Eli Lilly And Company	Imidazolinyl tachykinin receptor antagonists
US5607947A (en) *	1995-02-21	1997-03-04	Eli Lilly And Company	Pyrrolidinyl tachykinin receptor antagonists
IL116249A (en) *	1994-12-12	2003-07-06	Pfizer	Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
TW382017B (en) *	1995-12-27	2000-02-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
US6214846B1 (en) *	1997-06-27	2001-04-10	Merck Sharp & Dohme Limited	Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
US5972938A (en) *	1997-12-01	1999-10-26	Merck & Co., Inc.	Method for treating or preventing psychoimmunological disorders
DK1394150T3 (da) *	1999-02-24	2011-03-21	Hoffmann La Roche	4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
BR0008494A (pt) *	1999-02-24	2002-02-05	Hoffmann La Roche	Derivados de 3-fenilpiridina e seu uso como antagonista do receptor de nk-1
GB9923748D0 (en) *	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
ES2208205T3 (es) *	1999-11-29	2004-06-16	F. Hoffmann-La Roche Ag	2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
US6303790B1 (en) *	1999-11-29	2001-10-16	Hoffman-La Roche Inc.	Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) *	2000-01-18	2000-02-10	James Cook University	Brain injury treatment

2002
- 2002-07-02 US US10/187,587 patent/US20030083345A1/en not_active Abandoned
- 2002-07-03 WO PCT/EP2002/007323 patent/WO2003006016A2/fr active IP Right Grant
- 2002-07-03 KR KR1020047000395A patent/KR100589106B1/ko active IP Right Grant
- 2002-07-03 HU HU0401210A patent/HUP0401210A3/hu unknown
- 2002-07-03 AU AU2002328837A patent/AU2002328837B2/en not_active Expired
- 2002-07-03 CA CA2451566A patent/CA2451566C/fr not_active Expired - Lifetime
- 2002-07-03 MX MXPA04000278A patent/MXPA04000278A/es active IP Right Grant
- 2002-07-03 EP EP05017203A patent/EP1621195A3/fr not_active Withdrawn
- 2002-07-03 IL IL15935002A patent/IL159350A0/xx unknown
- 2002-07-03 CN CNB028135423A patent/CN100346789C/zh not_active Expired - Lifetime
- 2002-07-03 PL PL369535A patent/PL211246B1/pl unknown
- 2002-07-03 EP EP02764617A patent/EP1406618A2/fr not_active Withdrawn
- 2002-07-03 JP JP2003511822A patent/JP2004536119A/ja active Pending
- 2002-07-03 NZ NZ530107A patent/NZ530107A/en unknown
- 2002-07-03 BR BR0210893-3A patent/BR0210893A/pt not_active IP Right Cessation
- 2002-07-03 RU RU2004102397/15A patent/RU2304435C2/ru active
- 2002-07-05 PA PA20028549901A patent/PA8549901A1/es unknown
- 2002-07-08 PE PE2002000610A patent/PE20030238A1/es not_active Application Discontinuation
- 2002-07-08 AR ARP020102546A patent/AR037008A1/es unknown
- 2002-07-09 UY UY27374A patent/UY27374A1/es not_active Application Discontinuation
- 2002-07-09 GT GT200200143A patent/GT200200143A/es unknown
2003
- 2003-12-22 HR HR20031071A patent/HRP20031071A2/xx not_active Application Discontinuation
2004
- 2004-01-07 NO NO20040057A patent/NO332847B1/no not_active IP Right Cessation
- 2004-01-08 ZA ZA2004/00138A patent/ZA200400138B/en unknown
2005
- 2005-01-17 HK HK05100430A patent/HK1068266A1/xx not_active IP Right Cessation
2006
- 2006-07-05 US US11/481,216 patent/US20060247240A1/en not_active Abandoned
2010
- 2010-09-21 US US12/886,691 patent/US20110053954A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20040029362A (ko)	2004-04-06
WO2003006016A3 (fr)	2003-07-31
EP1406618A2 (fr)	2004-04-14
AU2002328837B2 (en)	2005-05-05
CN100346789C (zh)	2007-11-07
NO20040057L (no)	2004-01-07
CA2451566A1 (fr)	2003-01-23
US20110053954A1 (en)	2011-03-03
GT200200143A (es)	2002-11-11
WO2003006016A2 (fr)	2003-01-23
PL369535A1 (en)	2005-05-02
RU2004102397A (ru)	2005-04-20
RU2304435C2 (ru)	2007-08-20
HUP0401210A3 (en)	2011-07-28
PE20030238A1 (es)	2003-03-19
UY27374A1 (es)	2003-03-31
NZ530107A (en)	2006-01-27
PL211246B1 (pl)	2012-04-30
HRP20031071A2 (en)	2004-06-30
CA2451566C (fr)	2013-09-10
KR100589106B1 (ko)	2006-06-14
BR0210893A (pt)	2004-06-22
HK1068266A1 (en)	2005-04-29
ZA200400138B (en)	2005-06-29
US20060247240A1 (en)	2006-11-02
US20030083345A1 (en)	2003-05-01
AR037008A1 (es)	2004-10-20
HUP0401210A2 (hu)	2004-10-28
EP1621195A2 (fr)	2006-02-01
JP2004536119A (ja)	2004-12-02
MXPA04000278A (es)	2004-05-04
EP1621195A3 (fr)	2010-01-06
IL159350A0 (en)	2004-06-01
CN1523988A (zh)	2004-08-25
PA8549901A1 (es)	2003-01-24

Legal Events

Date	Code	Title	Description
2022-07-11	MK1K	Patent expired

Publication	Publication Date	Title
NO332847B1 (no)	2013-01-21	Anvendelse av NK-1 reseptor antagonister for fremstilling av et medikament for intravenos formulering for behandling og/eller forebygging av hjerne, ryggmarg eller nerveskade
AU2020217342B2 (en)	2021-10-07	Methods of increasing tonic inhibition and treating secondary insomnia
TWI684450B (zh)	2020-02-11	猝倒症之治療
AU2002328837A1 (en)	2003-05-22	Use of NK-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
JP2018162302A (ja)	2018-10-18	抗不安薬組成物、製剤および使用方法
WO2022120289A1 (fr)	2022-06-09	Rétablissement d'une lésion post-neurologique de fonction motrice à l'aide de substances psychédéliques
TW201141486A (en)	2011-12-01	Pharmaceutical composition for treating macular edema
JP2011207905A (ja)	2011-10-20	脳虚血疾患を予防及び治療する薬剤の製造におけるｌ−ブチルフタリドの使用
JP2002518442A (ja)	2002-06-25	偏頭痛及び情動病の治療及び予防用バルプロ酸類似物の用法
KR20120103557A (ko)	2012-09-19	파킨슨씨병 치료용 조성물 및 치료방법
JPWO2006009093A1 (ja)	2008-05-01	睡眠障害の予防および／または治療剤
WO2021234642A1 (fr)	2021-11-25	Association d'acétylleucine et de 4-aminopyridine ou d'acétazolamide pour traiter l'ataxie
JP2010536827A (ja)	2010-12-02	ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体
JPWO2004035053A1 (ja)	2006-02-09	神経栄養因子産生促進剤
CN102499914A (zh)	2012-06-20	一种治疗脑中风的药物
JPH02501389A (ja)	1990-05-17	多発性硬化症及び筋萎縮側索硬化症の治療用薬用製剤
CN114980874A (zh)	2022-08-30	肌痛性脑脊髓炎/慢性疲劳症候群治疗剂
Trounce	1972	Drugs in Current Use
EA025500B1 (ru)	2016-12-30	(1R,4R)-6'-ФТОР-(N-МЕТИЛ- ИЛИ N,N-ДИМЕТИЛ-)-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН ДЛЯ ЛЕЧЕНИЯ ФИБРОМИАЛГИИ И СИНДРОМА ХРОНИЧЕСКОЙ УСТАЛОСТИ
US20200138769A1 (en)	2020-05-07	Pharmaceutical composition
JPH06211665A (ja)	1994-08-02	ジラゼプを必須成分とする眼圧降下剤
WO1998026778A1 (fr)	1998-06-25	Medicaments pour traiter/prevenir les mouvements anormaux qui accompagnent les troubles du systeme nerveux extrapyramidal
Richards	2005	Applied pharmacology pertaining to the trauma patient
KR20090114371A (ko)	2009-11-03	다발성 경화증 치료제